Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This study describes characteristics of phase 1 trials, frequency of harms, and communication between investigators and research ethics committees about adverse events to characterize the safety and improve the regulatory review of UK phase 1 trials.

More information Original publication

DOI

10.1001/jama.2017.1471

Type

Journal article

Publication Date

2017-05-02T00:00:00+00:00

Volume

317

Pages

1799 - 1801

Total pages

2

Keywords

Clinical Trials, Phase I as Topic, Diagnosis-Related Groups, Humans, Information Dissemination, Pharmaceutical Preparations, Research Design, United Kingdom